As mutation rate is concerned, TP53 mutations were identified to be >2-fold enriched in recurrent or metastatic tumors (15.2% cases with TP53 mutation) vs. primary tumors (6.4% mutation rate of TP53). The gene discussed is TP53; the disease is metastatic neoplasm.